JUL 31, 2014
Comprehensive Ophthalmology, Glaucoma
Alcon’s Simbrinza, a combination of brinzolamide and brominidine, has been approved by the European Commission to decrease elevated IOP in patients with open-angle glaucoma or ocular hypertension for whom monotherapy has been insufficient.
Simbrinza is expected to launch in the United Kingdom during the third quarter of this year, followed by other European markets later in 2014 and in 2015. It has been available in the United States since 2013.
Designed to be administered with one drop twice daily, Simbrinza offers a simplified treatment schedule compared with use of its components separately.